SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-21-011923
Filing Date
2021-02-04
Accepted
2021-02-04 07:05:22
Documents
13
Period of Report
2021-02-04
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm215316d1_8k.htm   iXBRL 8-K 25845
2 EXHIBIT 99.1 tm215316d1_ex99-1.htm EX-99.1 69226
  Complete submission text file 0001104659-21-011923.txt   280269

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA bcli-20210204.xsd EX-101.SCH 3208
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE bcli-20210204_lab.xml EX-101.LAB 34592
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE bcli-20210204_pre.xml EX-101.PRE 22725
6 EXTRACTED XBRL INSTANCE DOCUMENT tm215316d1_8k_htm.xml XML 3617
Mailing Address 1325 AVENUE OF AMERICAS 28TH FLOOR NEW YORK NY 10019
Business Address 1325 AVENUE OF AMERICAS 28TH FLOOR NEW YORK NY 10019 201-488-0460
BRAINSTORM CELL THERAPEUTICS INC. (Filer) CIK: 0001137883 (see all company filings)

IRS No.: 207273918 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36641 | Film No.: 21588834
SIC: 2836 Biological Products, (No Diagnostic Substances)